Suppr超能文献

解析 1 型糖尿病中的遗传风险变异。

De-coding genetic risk variants in type 1 diabetes.

机构信息

Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, Diabetes Institute, University of Florida, Gainesville, FL, 32610, USA.

Department of Pediatrics, College of Medicine, Diabetes Institute, University of Florida, Gainesville, FL, 32610, USA.

出版信息

Immunol Cell Biol. 2021 May;99(5):496-508. doi: 10.1111/imcb.12438. Epub 2021 Feb 24.

Abstract

The conceptual basis for a genetic predisposition underlying the risk for developing type 1 diabetes (T1D) predates modern human molecular genetics. Over half of the genetic risk has been attributed to the human leukocyte antigen (HLA) class II gene region and to the insulin (INS) gene locus - both thought to confer direction of autoreactivity and tissue specificity. Notwithstanding, questions still remain regarding the functional contributions of a vast array of minor polygenic risk variants scattered throughout the genome that likely influence disease heterogeneity and clinical outcomes. Herein, we summarize the available literature related to the T1D-associated coding variants defined at the time of this review, for the genes PTPN22, IFIH1, SH2B3, CD226, TYK2, FUT2, SIRPG, CTLA4, CTSH and UBASH3A. Data from genotype-selected human cohorts are summarized, and studies from the non-obese diabetic (NOD) mouse are presented to describe the functional impact of these variants in relation to innate and adaptive immunity as well as to β-cell fragility, with expression profiles in tissues and peripheral blood highlighted. The contribution of each variant to progression through T1D staging, including environmental interactions, are discussed with consideration of how their respective protein products may serve as attractive targets for precision medicine-based therapeutics to prevent or suspend the development of T1D.

摘要

1 型糖尿病 (T1D) 发病风险的遗传易感性的概念基础可以追溯到现代人类分子遗传学之前。超过一半的遗传风险归因于人类白细胞抗原 (HLA) Ⅱ类基因区域和胰岛素 (INS) 基因座 - 两者都被认为赋予了自身反应性和组织特异性。尽管如此,对于散布在基因组中的大量微小多基因风险变异体的功能贡献仍存在疑问,这些变异体可能影响疾病异质性和临床结果。在此,我们总结了与本综述时定义的 T1D 相关的编码变异体相关的现有文献,这些基因包括 PTPN22、IFIH1、SH2B3、CD226、TYK2、FUT2、SIRPG、CTLA4、CTSH 和 UBASH3A。总结了来自基因分型人类队列的数据,并介绍了非肥胖型糖尿病 (NOD) 小鼠的研究,以描述这些变异体在先天和适应性免疫以及β细胞脆弱性方面的功能影响,并强调了组织和外周血中的表达谱。讨论了每个变异体对 T1D 分期进展的贡献,包括环境相互作用,并考虑了它们各自的蛋白产物如何作为基于精准医学的治疗方法的有吸引力的靶点,以预防或中止 T1D 的发展。

相似文献

1
De-coding genetic risk variants in type 1 diabetes.
Immunol Cell Biol. 2021 May;99(5):496-508. doi: 10.1111/imcb.12438. Epub 2021 Feb 24.
2
Type 1 Diabetes and Autoimmune Thyroid Disease-The Genetic Link.
Front Endocrinol (Lausanne). 2021 Mar 10;12:618213. doi: 10.3389/fendo.2021.618213. eCollection 2021.
3
LADA and T1D in Estonian population - two different genetic risk profiles.
Gene. 2012 Apr 15;497(2):285-91. doi: 10.1016/j.gene.2012.01.089. Epub 2012 Feb 3.
4
Association of variants in PTPN22, CTLA-4, IL2-RA, and INS genes with type 1 diabetes in Emiratis.
Ann Hum Genet. 2021 Mar;85(2):48-57. doi: 10.1111/ahg.12406. Epub 2020 Sep 24.
5
Improving prediction of type 1 diabetes by testing non-HLA genetic variants in addition to HLA markers.
Pediatr Diabetes. 2014 Aug;15(5):355-62. doi: 10.1111/pedi.12092. Epub 2013 Nov 8.
7
Association analysis of PTPN22, CTLA4 and IFIH1 genes with type 1 diabetes in Colombian families.
J Diabetes. 2015 May;7(3):402-10. doi: 10.1111/1753-0407.12192. Epub 2014 Sep 10.
10

引用本文的文献

1
Immune perturbations in human pancreas lymphatic tissues prior to and after type 1 diabetes onset.
Nat Commun. 2025 May 18;16(1):4621. doi: 10.1038/s41467-025-59626-0.
4
Immune perturbations in human pancreas lymphatic tissues prior to and after type 1 diabetes onset.
bioRxiv. 2024 Sep 16:2024.04.23.590798. doi: 10.1101/2024.04.23.590798.
6
Identification of functional enhancer variants associated with type I diabetes in CD4+ T cells.
Front Immunol. 2024 Jun 14;15:1387253. doi: 10.3389/fimmu.2024.1387253. eCollection 2024.
8
Genetic and Epigenetic Aspects of Type 1 Diabetes Mellitus: Modern View on the Problem.
Biomedicines. 2024 Feb 8;12(2):399. doi: 10.3390/biomedicines12020399.
9
Gene-environment interaction in the pathophysiology of type 1 diabetes.
Front Endocrinol (Lausanne). 2024 Jan 26;15:1335435. doi: 10.3389/fendo.2024.1335435. eCollection 2024.

本文引用的文献

1
Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes.
Nat Genet. 2021 Jul;53(7):962-971. doi: 10.1038/s41588-021-00880-5. Epub 2021 Jun 14.
2
CD226 Deletion Reduces Type 1 Diabetes in the NOD Mouse by Impairing Thymocyte Development and Peripheral T Cell Activation.
Front Immunol. 2020 Sep 4;11:2180. doi: 10.3389/fimmu.2020.02180. eCollection 2020.
3
Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells.
Sci Transl Med. 2020 Aug 19;12(557). doi: 10.1126/scitranslmed.aaz3866.
4
Next steps in the identification of gene targets for type 1 diabetes.
Diabetologia. 2020 Nov;63(11):2260-2269. doi: 10.1007/s00125-020-05248-8. Epub 2020 Aug 14.
6
Preclinical evaluation of tyrosine kinase 2 inhibitors for human beta-cell protection in type 1 diabetes.
Diabetes Obes Metab. 2020 Oct;22(10):1827-1836. doi: 10.1111/dom.14104. Epub 2020 Jul 5.
7
Innate inflammation drives NK cell activation to impair Treg activity.
J Autoimmun. 2020 Mar;108:102417. doi: 10.1016/j.jaut.2020.102417. Epub 2020 Feb 6.
8
Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.
Diabetes Care. 2020 Jan;43(1):5-12. doi: 10.2337/dc19-0880. Epub 2019 Nov 21.
9
Breast milk-derived human milk oligosaccharides promote Bifidobacterium interactions within a single ecosystem.
ISME J. 2020 Feb;14(2):635-648. doi: 10.1038/s41396-019-0553-2. Epub 2019 Nov 18.
10
UBASH3A Regulates the Synthesis and Dynamics of TCR-CD3 Complexes.
J Immunol. 2019 Dec 1;203(11):2827-2836. doi: 10.4049/jimmunol.1801338. Epub 2019 Oct 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验